Prokidney (PROK) Return on Sales (2024 - 2026)

Prokidney (PROK) reported Return on Sales of 1.89% for Q1 2026, down 24.0% year-over-year from 2.48% in Q1 2025, and down 3.87% quarter-over-quarter from 1.82% in Q4 2025.

Prokidney (PROK) Return on Sales (2024 - 2026) Analysis & Trends

Prokidney (PROK) has 3 years of Return on Sales data on file, last reported at 1.89% in Q1 2026.

  • Return on Sales for Q1 2026 came in at 1.89%, down 24.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1.76% (up 367.0% YoY), and the FY2025 annual result was 1.7%, up 1979.0% from the prior year.
  • Return on Sales slipped to 1.89% in Q1 2026 per PROK's latest filing, from 1.82% in the prior quarter.
  • Over five years, Return on Sales peaked at 1.65% in Q1 2025 and troughed at 6.38% in Q4 2024.
  • A 3-year average of 2.51% and a median of 1.74% in 2025 frame the typical range for Return on Sales.
  • The sharpest annual moves came in 2025 and 2026: Return on Sales jumped 456 bps in 2025, then fell 24 bps in 2026.
  • A 3-year view of Return on Sales shows it stood at 6.38% in 2024, then soared by 72 bps to 1.82% in 2025, then retreated by 4 bps to 1.89% in 2026.
  • Business Quant data shows PROK's Return on Sales at 1.89% in Q1 2026, 1.82% in Q4 2025, and 1.65% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.00%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 0.00%
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 0.00%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Prokidney 259.01 Mn 1.55 Bn - -1.89%

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.89%
Dec 31, 2025 -1.82%
Sep 30, 2025 -1.65%
Jun 30, 2025 -1.67%
Mar 31, 2025 -1.65%
Dec 31, 2024 -6.38%